Abstract Interstitial lung disease (ILD) is the most frequent organ involvement (found in nearly half) of myositis patients, but it reveals various clinical courses and therapeutic responsiveness according to clinical and serological subsets.
Introduction
Idiopathic inflammatory myositis (IIM), including polymyositis (PM)/dermatomyositis (DM), refers to a group of systemic inflammatory disorders that involve not only the muscle and skin but also many organs, such as joints, the heart, and the lungs. Several autoantibodies can be detected in sera from PM/DM patients, some of which are specific to PM/DM (known as myositis-specific autoantibodies [MSAs]) or myositis overlap syndrome (known as myositis-associated autoantibodies [MAAs] ). These autoantibodies are closely associated with subsets, complications, reactivity to therapy, and prognosis of PM/DM [1] .
Interstitial lung disease (ILD), or interstitial pneumonia (IP) is the most common internal organ manifestation that affects the prognosis of PM/DM patients. Therefore, diagnosis and evaluation of ILD is also very important to determine the treatment strategy when PM/ DM is diagnosed [2•, 3•, 4•] .
Recently, two types of MSAs, namely anti-aminoacyl transfer RNA synthetases and anti-CADM-140 (MDA5/ IFIH1) antibodies, have been elucidated to be closely associated with ILD in myositis. Moreover, ILD associated with these two antibodies represents completely different clinical subsets, providing us with useful information for predicting the clinical course and prognosis of ILD and for administering the optimal treatment. In this article, we review recent advances and update on the clinical subsets, biomarkers, and treatment of ILD associated with PM and DM.
Epidemiologic Aspect of Interstitial Lung Disease in Myositis
The prevalence of ILD in myositis has been reviewed in many myositis cohorts. In an earlier era, lung involvement in PM/DM had been considered to be rather rare, as only 5% was reported in a review by Frazier and Miller [5] in 1974. However, the development and routine use of CT scan enables to detect early interstitial changes in the lung, and as a result, the prevalence of ILD has become increased. In the recent cohort studies (single and multicenter), the prevalence of ILD in myositis has reached close to 50%, ranging from 21% to 78% [6] [7] [8] [9] [10] [11] [12] [13] .
PM/DM patients with accompanying ILD have poorer prognosis than those without ILD [9] [10] [11] . Prevalence of ILD seems to be similar in both PM and DM, but DM-ILD has an obviously more severe course, is more refractory to treatment, and carries a poorer prognosis than PM-ILD [14, 15, 16•] . This may be attributed to the presence of anti-CADM-140 antibody, a poor prognostic marker of DM and amyopathic DM, which may be included in cohorts of DM-ILD (as discussed later).
Autoantibodies Associated with Interstitial Lung Disease in Myositis: Association Between Clinical and Serological Subsets of Myositis-Interstitial Lung Disease
Several autoantibodies can be detected in sera from IIM patients and are closely associated with clinical subsets of IIM. In these MSAs, anti-aminoacyl transfer RNA synthetases and anti-CADM-140 (MDA5/IFIH1) antibodies have been known to be closely associated with ILD in myositis. However, ILD associated with these two antibodies represents different clinical subsets with different clinical courses, prognoses and responses to therapy (Table 1) .
Anti-Aminoacyl-Transfer RNA Synthetase Antibodies and Interstitial Lung Disease Aminoacyl-transfer RNA synthetases (ARS or synthetase) are the enzymes that catalyze the binding of amino acids to their corresponding transfer RNAs, and so there are 20 kinds of synthetases. Among MSAs, antisynthetase antibodies are found most frequently in PM/DM patients, and eight different autoantibodies reacting with different synthetases have been identified thus far: anti-Jo-1 (histidyl) [17, 18] , anti-PL-7 (threonyl) [19] , anti-PL-12 (alanyl) [20] , anti-EJ (glycyl) [21] , anti-OJ (isoleucyl) [22] , anti-KS (asparaginyl) [23] , anti-Zo (phenylalanyl) [24] , and anti-tyrosyl-tRNA synthetase antibodies [25] . With a few exceptions, each patient has only one of these autoantibodies, but patients show similar clinical manifestations, including ILD, myositis, arthritis, fever, Raynaud's phenomenon, and mechanic's hand, called antisynthetase syndrome [26] . ILD is the most frequent extramuscular manifestation and is found in 79% to 95% of patients with antisynthetase antibodies [27] [28] [29] [30] 31 •].
Although antisynthetase-positive patients show similar clinical manifestations of antisynthetase syndrome, some detailed clinical studies suggest that there are some differences in clinical manifestations among patients with different antisynthetase antibodies. Anti-Jo-1 is closely associated with high prevalence of both myositis and ILD, whereas anti-OJ, anti-PL-12, and anti-KS have stronger associations with ILD than myositis [32, 33, 34•, 35] . Anti-PL-7 antibody may be associated with PM-scleroderma overlap syndrome as well as ILD [36] .
Detailed clinical features of ILD in patients with antisynthetase antibodies have been described in several reports. [38] [39] [40] . Anti-SS-A/Ro antibody in patients with antisynthetase syndrome seems to be associated with the development of a more severe form of ILD [39] , a more frequent association with fibrosis of lung, and lesser efficacy of immunosuppressive therapy [40] .
The production of disease-specific autoantibodies may closely correlate with pathogenic mechanisms of inflammatory myopathy. Patients with antibodies to different synthetases show the same clinical syndrome. This strongly suggests that the immune response to molecules with analogous functions leads to a similar clinical syndrome. However, the pathophysiologic role of antisynthetase antibodies in myositis and/ or ILD remains to be clarified. Several reports suggest a possible pathogenic role of antisynthetases.
In an animal model, immunized mice with murine Jo-1 antigen generated specific B and T cells targeting speciesspecific epitopes of murine Jo-1 and developed a phenotype consistent with muscle and lung inflammation resembling features of human antisynthetase syndrome [41] . Sera from anti-Jo-1-positive PM-ILD patients induced a significant effect on the expression of ICAM-1 from human lung endothelial cells [42•] , although autoantibodies themselves might not be the endothelial cell-activating factor, as purified IgG did not induce ICAM-1 expression.
Recent reports demonstrate that certain synthetase molecules (histidyl-, asparaginyl-, and seryl-tRNA synthetases) and their proteolytic fragments have chemokine-like activities against inflammatory cells such as CD4 + and CD8 + T cells and activated monocytes and immature dendritic cells [43] . Mononuclear cells expressing chemokine receptors such as CCR3 and CCR5 infiltrate muscle tissues of myositis patients, but not healthy muscle, supporting the results that histidyl-and asparaginyl-tRNA synthetases activate CCR5 + and CCR3 + cells, respectively [43] . These findings indicate that the liberation of autoantigenic synthetases from damaged tissues may recruit inflammatory mononuclear cells and perpetuate the inflammation process of myositis and ILD, and also induce autoimmune responses to autoantigens.
Anti-CADM-140 (MDA5/IFIH1) Antibody and Interstitial Lung Disease
Amyopathic DM (ADM) and clinical ADM (C-ADM) are defined as disorders that show the typical skin manifestations of DM but no or little evidence of clinical myositis [44, 45] . It is known that C-ADM patients, mostly in Asian countries, frequently develop life-threatening acute, progressive ILD [46] [47] [48] [49] [50] .
Until recently, it was thought that MSAs could not be detected in patients with C-ADM, and this appeared to be a characteristic feature. In 2005, however, Sato et al. [51] reported the identification of a specific autoantibody in C-ADM patients. They screened the sera of 314 patients and controls by 35 S-methionine-labeled protein immunoprecipitation and immunoblotting techniques using K562 cells, and Nakashima et al. [52••] reported the characteristics of anti-CADM-140-positive patients. In the screening of 192 patients with various connective tissue diseases, 13 were revealed to be positive with anti-CADM-140 antibody. All anti-CADM-140-positive patients with DM had either typical DM (2 cases) or C-ADM (11 cases), and 9 (69%) patients had fever higher than 38°C, while 12 patients (92%) had ILD and 7 (54%) developed acute, progressive ILD. Prognosis was significantly poorer in anti-CADM-140-positive patients than in anti-CADM-140-negative DM patients, and 6 (46%) died of respiratory failure within 6 months of the onset of disease. Interestingly, the serum ferritin concentrations in 11 of the anti-CADM-140-positive patients were already elevated within 1 month of their admission, with significantly high frequency in comparison with anti-CADM-negative DM patients (85% vs 33%; P0 0.005). Moreover, the serum ferritin level correlated with the activity of ILD in anti-CADM-140-positive patients.
ILD in anti-CADM-140-positive patients was correlated with abnormalities in serum hepatobiliary enzymes and interleukin-18, which worsened in accordance with ILD and ferritin levels [57••, 58] . Thus, the anti-CADM-140 antibody appeared to be associated with macrophage activation syndrome developed in C-ADM and intractable acute ILD.
The target autoantigen of anti-CADM-140 antibody was identified as melanoma differentiation-associated gene 5 (MDA5), also known as interferon induced with helicase C domain protein 1 (IFIH1) [ Finding MDA5/IFIH1 as the autoantigen specifically recognized by one of the DM-specific autoantibodies is strikingly interesting because many reports have suggested the possible association between myositis and viral infections [60] [61] [62] , in particular Coxsackie B virus belonging to the picornaviruses that are targeted by MDA5/IFIH1. To increase our understanding of the pathophysiology of acute ILD accompanied by C-ADM and to develop more effective therapy, whether anti-CADM-140 antibody and its target antigen, MDA5/IFIH1, have pathogenic roles in ILD and C-ADM should be elucidated.
Radiological and Histopathological Findings of Interstitial Lung Disease in Myositis
In histopathological analysis by VATS or TBLB, nonspecific interstitial pneumonia (NSIP) is the most frequent histologic pattern of ILD in myositis, but usual interstitial pneumonia (UIP), organizing pneumonia (OP), and diffuse alveolar damage (DAD) can also be found, though less frequently [14, [63] [64] [65] . These histologic findings are partially, but not always, associated with the underlying disease (PM or DM), clinical course (acute or chronic), and autoantibody profiles. While NSIP is widely found in both PM and DM, UIP is associated with chronic ILD (both PM and DM), and DAD is characteristically found in acute refractory ILD in DM and C-ADM. OP shows a good response to glucocorticoid therapy. High-resolution CT (HRCT) scanning of the chest is a most sensitive technique to detect ILD and provide information for prognosis and response of treatment.
Typical HRCT findings in myositis-associated ILD include ground glass opacities (GGO), micronodules, linear and reticular opacities, peribronchovascular or subpleural consolidation, irregularity of interface, and traction bronchiectasis (Fig. 1) [15, 46, 65, 66] . These findings are compatible with NSIP. Honeycombing pattern suggesting UIP is also found in ILD-myositis, but with lower frequency. Recent studies suggest characteristics of HRCT findings in two myositis/ILD-associated autoantibodies. Watanabe et al. [67•] reported the HRCT and pathological findings in 13 ILD cases with antisynthetase syndrome but without clinical myositis. Pleural irregularities and/or prominent interlobular septa, GGO, reticulation, and traction bronchiectasis were the major findings, while honeycombing was not found in any cases. Although most of these cases showed histologic NSIP if lung biopsies were applied, even in cases with pathological diagnosis of UIP, HRCT findings were not compatible with a typical UIP pattern showing honeycombing.
Tanizawa et al. [68••] described HRCT findings of ILD in DM/C-ADM with anti-CADM-140 antibody. GGO, nonseptal linear or plate-like opacity, and consolidation were the common findings in ILD of both antibody-positive and negative DM. However, intralobular reticular opacities (abnormal thickening of intralobular interstitial tissues) found in the antibody-negative ILD was significantly less in the positive ILD patients. Moreover, lower consolidation/GGO pattern (lower peripheral or peribronchovascular consolidation or GGO) and random GGO pattern (random peripheral GGO) were mainly found in anti-CADM-140-positive patients, whereas lower reticulation pattern (lower peripheral or peribronchovascular reticulation) was the main finding among anti-CADM-140-negative patients. The latter HRCT pattern is compatible with NSIP and likely with that of anti-synthetase-positive ILD patients, while three patients who were negative for both anti-CADM-140 and antisynthetases showed lower reticulation pattern as well. Thus, HRCT of anti-CADM-140-positive DM/C-ADM-ILD is characterized by lower consolidation/GGO and random GGO patterns and the absence of intralobular reticular opacities, which are different from typical NSIP patterns (Fig. 1) .
A lower reticulation pattern is consistent with NSIP and likely with that of antisynthetase-positive ILD patients. On the other hand, lower consolidation/GGO and random GGO patterns in anti-CADM-140-positive ILD are hard to interpret because the pathological approach is usually difficult in the early stage of the disease. Lower consolidation/GGO may represent OP or localized DAD [68••] . These findings and the absence of lower reticulation and intralobular reticular opacities in anti-CADM-140-positive ILD may suggest a lower prevalence of pathological NSIP.
Biomarkers of Interstitial Lung Disease in Myositis
There are no specific serum biomarkers for myositisassociated ILD. Nevertheless, certain serum markers predicting activity of ILD should be necessary, as a correlation is often not recognized between activities of myositis and ILD. HRCT of the lung is the most valuable and sensitive method to detect and predict the activity of ILD, but frequent examination should be avoided because of the risk of high-radiation exposure by CT. Several biomarkers that may reflect inflammatory activity of lung have been utilized. KL-6 and SP-D KL-6 (Krebs von den Lungen-6) is a mucin-like glycoprotein expressed in type II alveolar epithelial cells. Because serum level of KL-6 increases by reflecting hyper-expression of KL-6-producing cells and alveolar injury in ILD, its detection is useful as a serologic biomarker for diagnosis and monitoring ILD. Several studies suggested the usefulness of KL-6 in disease activity, therapeutic response, and prognosis for myositis-ILD [69] [70] [71] [72] [73] [74] . Satoh et al. [72] demonstrated that a high serum level (>1,000 U/mL) of KL-6 was a poor prognostic factor in 152 idiopathic IP-and 67 connective tissue disease-associated ILD patients, including 16 PM/DM patients, before treatment [72] .
SP-D (surfactant protein-D) is a lung-specific surfactant lipoprotein secreted from type II alveolar epithelial cells. Serum level of SP-D reflects the activity of certain lung diseases such as ILD and pulmonary alveolar proteinosis [71, 73] . Compared with KL-6, SP-D appears to have the same specificity but lower sensitivity [71] . Gono et al. [75•] showed that the serum ferritin level before initial treatment in acute or subacute ILD in DM patients was significantly higher (mean, 790 ng/mL) than in chronic ILD (188 ng/mL) and non-ILD patients (160 ng/mL). Patients with a ferritin level more than 1,500 ng/mL showed significantly poorer prognosis than those with less than 1,500 ng/mL. They also reported that serum ferritin was significantly elevated in patients with anti-CADM-140 (MDA5)-positive acute ILD and correlated with prognosis and disease activity [57••, 76] .
Titers of Autoantibodies
It is not clear whether myositis-specific autoantibodies are directly involved in pathophysiologic mechanisms of myositis and ILD. Correlation between titers of such autoantibodies and activity of myositis or ILD is controversial. There are several reports that anti-Jo-1 antibody titers are correlated with activity of myositis as well as lung [77] , and anti-CADM-140 titer disappeared after intensive treatment of ILD in ADM patients [78] . However, these changes of antibody titers are modest, and further studies will be necessary before we can draw conclusions.
Treatment
Regarding the therapy of ILD in myositis, glucocorticoids are the empiric first-line drug, and additional immunosuppressive agents are often used as the second-line drugs in cases of refractory disease. However, these therapies are not based on high levels of evidence (ie, randomized controlled trials), but rather based on long-term experiences, retrospective studies, and small-scale case series or case reports. Because ILD is a progressive and fatal disease and glucocorticoids have been established as the standard therapy, it is difficult to conduct placebo-controlled, prospective trials.
Glucocorticoids
Oral high-dose glucocorticoids (>1 mg/kg per day of prednisone) or pulse therapy of methylprednisolone (1,000 mg intravenously for 3 days) are the first-line therapy for ILD in myositis. Roughly half of ILD patients with myositis respond well to the initial glucocorticoid therapy [14, 29, 37•, 79] . However, acute ILD, especially rapid, progressive ILD in anti-CADM-140-positive DM/C-ADM, is usually not responsive to glucocorticoids alone [51, 52••, 53•, 54-56] .
Fujisawa et al. [14] reported 28 ILD patients with myositis (16 PM and 12 DM) and their difference in efficacy of treatment. Glucocorticoids alone achieved a favorable response in six patients (37.5%) with PM-ILD, but in only one (8.3%) with DM-ILD. Overall 2.5-year survival in DM-ILD was 58%, and 5-year survival in PM-ILD was 81%. In a similar study by Nawata et al. [79] , when ILD was classified into two groups according to serum creatine kinase (CK) levels (high CK or normal CK), the normal CK group showed significantly more resistance to glucocorticoid therapy and poorer prognosis than those with high CK (1-year survival, 31% vs 89%) [79] .
Although these studies have not reported the autoantibody status, glucocorticoid-refractory ILD with DM (not PM) or normal CK patients may represent the characteristic features of patients with anti-CADM-140 antibody who have reported to have treatment resistance and poor prognosis. It has been obvious that the prognosis of initial glucocorticoid-resistant ILD patients is not improved even if immunosuppressive drugs are added after exacerbation of respiratory symptoms. The efficacy of glucocorticoids as the initial therapy of ILD is limited; nevertheless, glucocorticoids remain the mainstay of therapy.
Cyclophosphamide
Cyclophosphamide (CYC), oral or intravenous pulse (IVCYC), is commonly used in acute or refractory ILD and has demonstrated its efficacy in several case series and small-scale open-label trials [7, [80] [81] [82] . Yamasaki et al. [82] reported 17 cases of refractory ILD in myositis who were treated with IVCYC (300-800 mg/m 2 at least 6 times every 4 weeks) and who showed significant improvement in dyspnea, pulmonary function, and HRCT findings.
CYC is also used in combination with other immunosuppressive drugs in refractory ILD [83, 84] . Kameda et al. [84] reported the efficacy of IVCYC in combination with glucocorticoids and cyclosporine (CSP) in 10 DM patients with acute ILD. Although five patients who received the combination therapy died of respiratory failure within 3 months, the mortality rate tended to become lower than in the historical control, in which 9 of 12 patients died despite highdose glucocorticoid therapy with or without a choice of CYC, CSP, or azathioprine (AZT).
Calcineurin Inhibitors
Calcineurin inhibitors such as CSP and tacrolimus (TAC) targeting activated T cells by inhibiting calcineurin and nuclear translocation of NF-AT may become the cornerstone of the treatment of ILD in myositis.
Cyclosporine
Several retrospective or open-label studies have analyzed the efficacy of CSP in PM/DM-ILD [14, 37•, 79, 85, 86] . Takada et al. [86] reported a multicenter retrospective analysis of 38 cases with acute ILD in PM/DM. In this study, ILD in PM (9 cases) and chronic ILD in DM (5 cases) showed good efficacy of CSP and good prognosis, whereas patients with acute IP in DM showed poor response and poor prognosis (7 of 17 died). Moreover, in a further analysis of 32 cases with acute DM-ILD, 9 of 13 starting CSP within 2 weeks from initial glucocorticoid treatment survived (survival rate, 69%), whereas all 17 cases receiving only glucocorticoids more than 2 weeks as the initial therapy died within 9 months from the onset of therapy. In the retrospective study by Kotani et al. [87] analyzing the efficacy of CSP in 16 DM cases with acute or subacute ILD, 9 cases treated initially with glucocorticoids and CSP (mean interval, 3.8 days) appeared to show good prognosis (only 1 died), whereas 4 of 7 cases (57%) in whom CSP was added when initial glucocorticoid treatment was not effective (mean interval, 20.0 days) died of respiratory failure related to ILD [87] .
Monitoring of serum CSP concentration is important for achieving maximal efficacy and for reducing toxicity. Trough level (C0) and 2-hour postdose blood concentration (C2) are correlated with the therapeutic effects [88•, 89•] . Authors also suggest that once-daily preprandial administration of CSP, rather than twice daily, may be beneficial in DM patients with progressive ILD [89•] . These studies, although they were small-scale retrospective analyses, suggest the effectiveness of early intervention and tight control by CSP in combination with glucocorticoids in the treatment of refractory myositis-ILD.
Tacrolimus
TAC is another calcineurin inhibitor that is 100-fold more potent in inhibiting T-cell activity compared with CSP. TAC recently has been utilized in refractory ILD in myositis patients, as well as CSP. Several case series and retrospective studies have shown the efficacy and tolerability of TAC in patients with PM/DM-ILD refractory to CSP [86, [90] [91] [92] . TAC appears to be more effective in ILD of antisynthetase syndrome [91, 92] . Wilkes et al. [92] retrospectively analyzed 13 antisynthetase-positive patients treated with TAC and showed its efficacy (and that it was well-tolerated) for refractory ILD and myositis.
Rituximab
Rituximab is a biologic agent of chimeric monoclonal anti-CD20 antibody that targets B cells. Recently, its potential usefulness has been demonstrated in various autoimmune diseases, and several case reports and case series of rituximab have also been reported in myositis-ILD [93•, 94, 95] . Sem et al. [93• ] reported 11 refractory ILD in antisynthetase syndrome patients treated with rituximab and showed that rituximab stabilized and/or improved the ILD in 7 of 11. Rituximab reduced the serum titer of anti-Jo-1 antibody, but the effect was modest.
Other Immunomodulating Therapies

Methotrexate
Although methotrexate (MTX), inhibitor of folic acid and purine metabolisms, is widely used in treatment of refractory PM/DM, there is no obvious evidence in myositis-ILD. The use of MTX in ILD is controversial because there are patients who respond favorably to this treatment, but the risk of idiosyncratic drug-induced ILD has also been reported. Particular care should be taken if using MTX for ILD in myositis.
Azathioprine
AZT has been widely used in myositis and ILD as the second-line immunomodulating drug, but its efficacy is modest. AZT may be useful as a maintenance therapy for the control of ILD after CYC.
Mycophenolate Mofetil
In a few case series, the potential efficacy of mycophenolate mofetil has been shown in stabilization of progressive ILD and reducing glucocorticoid dose in ILD patients with connective tissue diseases, including PM/DM [96•, 97•] .
Intravenous Immunoglobulin
The efficacy of intravenous immunoglobulin has been demonstrated in muscular symptoms of refractory DM and PM, but the usefulness in ILD associated with myositis is uncertain. One case series of five patients with severe ILD reported its potential usefulness as a salvage therapy [98] .
Anticytokine Biologics
The use of anti-tumor necrosis factor [99, 100] and other biologics (including tocilizumab [101] and anakinra [102] ) has been reported in some case reports and case series and in a randomized pilot trial [100] . However, all of them focused on severe or refractory myopathy and not on ILD. They appear to be effective in myositis occasionally, but some reports suggest no effect or even worsening muscle symptoms [99] . Their efficacy in ILD has not been discussed. Experience with ant-cytokine therapies on myositis-ILD should be collected and investigated carefully.
Conclusions
ILD is the most frequent extramuscular organ involvement and the most important prognostic factor of IIM, but it reveals various clinical courses and therapeutic responsiveness according to the clinical and serological subsets. Autoantibodies as well as imaging and histopathological studies are useful for the classification of ILD in myositis and provide us with useful information for predicting the prognosis and determining therapeutic strategy. Routine examination of anti-CADM-140 antibody and antisynthetase antibodies, except for anti-Jo-1, is not available thus far, as these antibodies can only be detected using complicated immunoprecipitation techniques. Quantitative methods to detect these MSAs are now being developing and will be available in the near future.
As treatment of ILD in myositis, glucocorticoids remain the first-line drug, and various immunomodulating drugs are also frequently used in refractory patients. Among these drugs, CYC (especially IVCYC) and calcineurin inhibitors (CSP and TAC) appear to be the key drugs for the treatment of refractory ILD in myositis. Rituximab may be another candidate if these drugs are not effective. However, there are no large-scale, randomized clinical trials to guarantee the efficacy and safety of these drugs. Although it may be difficult to conduct placebo-controlled trials in such a progressive and fatal condition, the construction of evidence is necessary to achieve the best management of an intractable disease such as ILD.
